Immutep Ltd · ASX:IMM
Immutep — Shareholder Meeting (November 2024)
16 slides from Immutep's shareholder meeting presentation, Nov 22, 2024
Slide 1: Immutep AGM 2024 Presentation
Immutep AGM 2024 Presentation 22 November 2024 (ASX: IMM; NASDAQ: IMMP) Unlocking the power of the immune system to fight cancer and autoimmune disease
Slide 2: Forward-Looking Statements
Forward-Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarificati
Slide 3: Agenda
Agenda Overview of Immutep Highlights & Outlook Efti Program & Strategy IMP761 Program Summary 3
Slide 4: Overview of Immutep
: @ immutep Overview of Immutep
Slide 5: Company Overview
Company Overview Pure-play LAG-3 company with • Multiple LAG-3 Programs – Four clinical-stage assets and one preclinical deep pipeline in oncology & program autoimmune diseases: • Upcoming Milestones – Multiple data updates from clinical programs Lead candidate Efti addressing • First-in-class MOA –
Slide 6: Deep LAG-3 Pipeline in Oncology & Autoimmune Diseases
Deep LAG-3 Pipeline in Oncology & Autoimmune Diseases Program Indication Preclinical Phase I Phase II Late Stage# Collaborations Commercial Rights 1L Non-Small Cell Lung Cancer (NSCLC) TACTI-004 | Efti + Pembrolizumab + Chemo a 1L Head & Neck Squamous Cell Carcinoma (HNSCC) TACTI-003 | Efti + Pembro
Slide 7: Pioneering LAG-3 Immunotherapy Portfolio
Pioneering LAG-3 Immunotherapy Portfolio LAG-3 Immutep has designed multiple first-in-class Antigen-presenting cells (APC) T Cell therapeutics targeting either MHC Class II molecules on antigen-presenting cells (APC) or LAG-3 on T-cells MHC Class II to fight cancer & autoimmune disease Targeting MHC
Slide 8: Highlights & Outlook
: @ immutep Highlights & Outlook
Slide 9: 2024 Clinical Milestones
2024 Clinical Milestones Non-small cell Head and neck Metastatic lung cancer squamous cell breast cancer Soft tissue sarcoma carcinoma TACTI-004 TACTI-003 AIPAC-003 EFTISARC-NEO Phase III TACTI-004 trial (KEYNOTE-PNC-91) Phase IIb TACTI-003 trial evaluating efti in AIPAC-003 is an integrated Phase I
Slide 10: TACTI-004 Trial: Immutep & MSD Phase III Trial in NSCLC
TACTI-004 Trial: Immutep & MSD Phase III Trial in NSCLC Opportunity to set a new standard of care across entire NSCLC population regardless of PD-L1 expression Trial Overview: • TACTI-004 will be a 1:1 randomized, double-blind, multinational, controlled clinical study with ~750 patients • Trial will
Slide 11: INSIGHT-003: Excellent Mature Survival Data
INSIGHT-003: Excellent Mature Survival Data Promising efficacy & safety from first-in-human study evaluating Efti + KEYTRUDA + doublet chemo • Investigator-initiated Phase I study in first line metastatic non-squamous NSCLC regardless of PD-L1 (TPS 0-100) • Multi-centre trial led by the Frankfurt In
Slide 12: Soft Tissue Sarcoma: Orphan Disease with High Unmet Need
Soft Tissue Sarcoma: Orphan Disease with High Unmet Need Investigator-initiated trial studying novel triple combination of Efti + Radiotherapy + KEYTRUDA EFTISARC-NEO Phase II Trial Design* Screening Study treatment Follow up • First trial studying efti in neoadjuvant setting and with radiotherapy •
Slide 13: Commercial Manufacturing & Patent Protection
Commercial Manufacturing & Patent Protection Manufacturing at Commercial Scale Robust Intellectual Property Protection • Comparability of Drug Substance and Drug Product Efti manufactured at 2,000L scale achieved • Eight new patents granted in FY24: • Regulatory authorisation for efti manufactured a
Slide 14: FY24 Financial Summary
FY24 Financial Summary FY24 FY23 • Strong cash position of approx. A$172.3 million including investment in term deposit as of 30 Sept 2024 following A$100.2 million equity raise in June Revenue and other income A$7.8M A$5.2M 2024 G&A Expenses A$8.9M A$8.7M • Disciplined cash management strategy with
Slide 15: Outlook
Outlook 2024 • Non-Small Cell Lung Cancer – TACTI-004 preparations for study start in late 2024 / early 2025 • Head and Neck Squamous Cell Carcinoma – Update from Cohort B of TACTI-003 trial at the ESMO Immuno-Oncology Congress • Autoimmune Diseases – Safety data from IMP761 first-in-human Phase I t
Slide 16: Thank You
: =) immutep Thank You